LATEST NEWS
September 4, 2024
Venova Medical Announces $30 Million Series B
Venova Medical raised $30 million in Series B funding, co-led by Catalyst Health Ventures and a major medical device firm, with support from ShangBay Capital and others. The funds will advance U.S. clinical trials for its innovative hemodialysis access technology.
August 27, 2024
Ceribell files for a $100 million IPO
ShangBay Capital is proud to announce that Ceribell, one of our first portfolio companies, has filed for a $100 million IPO. Ceribell's pioneering AI-powered EEG platform is transforming neurological care by providing rapid diagnosis and continuous monitoring for seizure patients, addressing critical gaps in patient management and reducing healthcare costs. This milestone reflects both Ceribell's innovation and our commitment at ShangBay Capital to supporting companies that drive advancements in healthcare.
February 2, 2024
May 3, 2024
ShangBay Capital’s William Dai Recognized Among GrowthCap’s Top 25 Healthcare Investors for 2024
ShangBay Capital celebrates William Dai's recognition as one of GrowthCap's top healthcare investors for 2024. Dai, ShangBay's Founding Managing Partner, is praised for his impactful investments in medtech ventures, showcasing over two decades of finance and mergers expertise. With 67 nurtured portfolio companies and numerous successful exits, Dai's leadership highlights ShangBay's commitment to supporting innovative healthcare solutions amidst global challenges.
April 22, 2024
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration
Ipsen and Skyhawk Therapeutics have teamed up to develop groundbreaking treatments for rare neurological diseases using Skyhawk's RNA-targeting platform. Ipsen will handle further development and commercialization, with Skyhawk potentially receiving up to $1.8 billion in milestones and royalties. This partnership underscores a significant investment in innovative therapies for patients with unmet medical needs in the field of rare neurological disorders.
February 28, 2024
Skyhawk Therapeutics Progresses SKY-0515 Study in Huntington's Disease
Skyhawk Therapeutics, Inc. announces Phase 1 MAD initiation for SKY-0515 in Huntington's disease. Derived from their SKYSTAR® platform, SKY-0515 targets mutated huntingtin protein, offering potential benefits to patients lacking curative therapies. This marks a significant milestone in Skyhawk's quest for breakthrough treatments.
February 26, 2024
Laplace Interventional Announces Successful First in Human Procedure in Early Feasibility Study
Laplace Interventional, in collaboration with the Tucson Medical Center, achieved a medical breakthrough with the first-in-human implantation of its Transcatheter Tricuspid Valve Replacement (TTVR) system, targeting Tricuspid Regurgitation (TR). This minimally invasive procedure, conducted under FDA-approved study protocols, signals a promising advancement in cardiac care.
February 14, 2024
Neuro42 Receives FDA Clearance on Portable and Compact Brain MRI Scanner for Point of Care Imaging
Neuro42, a medical technology company, has obtained FDA clearance for its portable MRI scanner, eliminating the need for patient transport and improving diagnosis and treatment for neurological conditions. With a focus on accessibility and innovation, neuro42 aims to launch its MRI system in the US market this year, revolutionizing neuroimaging and surgical guidance.
Avation Medical raises $22M+ from impressive line-up of new global investors
Avation Medical, an innovative neuromodulation and digital health company, announced more than $22 million in equity financing in its oversubscribed Series C round, led by new investors ShangBay Capital and Asahi Kasei, which included Angelini Ventures, JobsOhio Growth Capital Fund, and others.
Janurary 17, 2024
2023 SVB Health Care Report
Shangbay Capital has been ranked the most-active healthcare device investor by Silicon Valley Bank in their 2023 Healthcare Annual Report.
January 4, 2024
HSBC Venture Healthcare Report 2023
Shangbay Capital has been ranked the #2 most-active healthcare device investor by the 2023 HSBC Healthcare Annual Report.